Sally B Coburn1, Frank Z Stanczyk2, Roni T Falk1, Katherine A McGlynn1, Louise A Brinton1, Joshua Sampson1, Gary Bradwin3, Xia Xu4, Britton Trabert5. 1. Division of Cancer Epidemiology and Genetics, National Cancer Institute, NIH, DHHS, Bethesda, MD, USA. 2. Departments of Obstetrics and Gynecology, and Preventive Medicine, University of Southern California Keck School of Medicine, Los Angeles, CA, USA. 3. Department of Laboratory Medicine, Harvard Medical School and Children's Hospital, Boston, MA, USA. 4. Cancer Research Technology Program, Leidos Biomedical Research, Inc., Frederick National Laboratory for Cancer Research, Frederick, MD, USA. 5. Division of Cancer Epidemiology and Genetics, National Cancer Institute, NIH, DHHS, Bethesda, MD, USA. britton.trabert@nih.gov.
Abstract
PURPOSE: The comparability between serum, plasma, and urinary measurements of estrogen metabolites via liquid chromatography-tandem mass spectrometry (LC-MS/MS) has not been largely explored, and it is unclear if urinary LC-MS/MS measurements are suitable surrogates of circulating levels. METHODS: Serum, plasma (EDTA and heparin), and urinary estrogen/estrogen metabolite levels were measured via LC-MS/MS in paired samples from 64 healthy volunteers (18 men, 20 premenopausal women, 26 postmenopausal women). Geometric means and Spearman correlation coefficients were used to compare individual and combined pathway levels of estrogens/estrogen metabolites across biologic matrices by sex/menopausal status. RESULTS: Measured concentrations of estrogens/estrogen metabolites across blood matrices were almost identical (percent differences < 4.8%). Parent estrogen concentrations measured in serum and urine were moderately correlated in postmenopausal women (estrone: r = 0.69, estradiol: r = 0.69). Correlations were similar comparing unconjugated serum estradiol to urinary estrone (r = 0.76) and urinary estradiol (r = 0.65) in postmenopausal women but were moderate to low in premenopausal women (r = 0.60, 0.40, respectively)/men (r = 0.33, 0.53, respectively). Comparing metabolite ratios, proportionally higher concentrations of 16-pathway metabolites were measured in urine versus serum across sex/menopausal status groups (e.g., postmenopausal women: 50.3% 16-pathway metabolites/total in urine versus 35.3% in serum). CONCLUSIONS: There is strong agreement between estrogen/estrogen metabolites measurements in serum, heparin plasma, and EDTA plasma. Individual estrogen metabolite concentrations were moderately correlated between urine and serum, but were not well correlated when evaluating pathway- or relative estrogen concentrations. Differences between serum and urine are likely explained by differences in metabolism and/or excretion.
PURPOSE: The comparability between serum, plasma, and urinary measurements of estrogen metabolites via liquid chromatography-tandem mass spectrometry (LC-MS/MS) has not been largely explored, and it is unclear if urinary LC-MS/MS measurements are suitable surrogates of circulating levels. METHODS: Serum, plasma (EDTA and heparin), and urinary estrogen/estrogen metabolite levels were measured via LC-MS/MS in paired samples from 64 healthy volunteers (18 men, 20 premenopausal women, 26 postmenopausal women). Geometric means and Spearman correlation coefficients were used to compare individual and combined pathway levels of estrogens/estrogen metabolites across biologic matrices by sex/menopausal status. RESULTS: Measured concentrations of estrogens/estrogen metabolites across blood matrices were almost identical (percent differences < 4.8%). Parent estrogen concentrations measured in serum and urine were moderately correlated in postmenopausal women (estrone: r = 0.69, estradiol: r = 0.69). Correlations were similar comparing unconjugated serum estradiol to urinary estrone (r = 0.76) and urinary estradiol (r = 0.65) in postmenopausal women but were moderate to low in premenopausal women (r = 0.60, 0.40, respectively)/men (r = 0.33, 0.53, respectively). Comparing metabolite ratios, proportionally higher concentrations of 16-pathway metabolites were measured in urine versus serum across sex/menopausal status groups (e.g., postmenopausal women: 50.3% 16-pathway metabolites/total in urine versus 35.3% in serum). CONCLUSIONS: There is strong agreement between estrogen/estrogen metabolites measurements in serum, heparin plasma, and EDTA plasma. Individual estrogen metabolite concentrations were moderately correlated between urine and serum, but were not well correlated when evaluating pathway- or relative estrogen concentrations. Differences between serum and urine are likely explained by differences in metabolism and/or excretion.
Authors: A Heather Eliassen; Stacey A Missmer; Shelley S Tworoger; Donna Spiegelman; Robert L Barbieri; Mitch Dowsett; Susan E Hankinson Journal: J Natl Cancer Inst Date: 2006-10-04 Impact factor: 13.506
Authors: Xia Xu; Timothy D Veenstra; Stephen D Fox; John M Roman; Haleem J Issaq; Roni Falk; Joseph E Saavedra; Larry K Keefer; Regina G Ziegler Journal: Anal Chem Date: 2005-10-15 Impact factor: 6.986
Authors: Kathleen A O'Connor; Eleanor Brindle; Darryl J Holman; Nancy A Klein; Michael R Soules; Kenneth L Campbell; Fortüne Kohen; Coralie J Munro; Jane B Shofer; Bill L Lasley; James W Wood Journal: Clin Chem Date: 2003-07 Impact factor: 8.327
Authors: Richard J Santen; Lawrence Demers; Susan Ohorodnik; J Settlage; Peter Langecker; D Blanchett; Paul E Goss; Shuping Wang Journal: Steroids Date: 2007-05-21 Impact factor: 2.668
Authors: Roni T Falk; Xia Xu; Larry Keefer; Timothy D Veenstra; Regina G Ziegler Journal: Cancer Epidemiol Biomarkers Prev Date: 2008-12 Impact factor: 4.254
Authors: Xia Xu; John M Roman; Haleem J Issaq; Larry K Keefer; Timothy D Veenstra; Regina G Ziegler Journal: Anal Chem Date: 2007-09-12 Impact factor: 6.986
Authors: Laura M Hack; Shota Nishitani; Anna K Knight; Varun Kilaru; Stephanie A Maddox; Antonia V Seligowski; Tanja Jovanovic; Kerry J Ressler; Alicia K Smith; Vasiliki Michopoulos Journal: Compr Psychoneuroendocrinol Date: 2021-03-09
Authors: Lusine Yaghjyan; Lancia N F Darville; Jayden Cline; Yessica C Martinez; Shannan Rich; Rebecca J Austin-Datta; John M Koomen; Shelley S Tworoger; Kathleen M Egan Journal: Cancer Causes Control Date: 2022-01-06 Impact factor: 2.532
Authors: Lancia N F Darville; Jayden K Cline; Carrie Rozmeski; Yessica C Martinez; Shannan Rich; Steven A Eschrich; Kathleen M Egan; Lusine Yaghjyan; John M Koomen Journal: J Chromatogr B Analyt Technol Biomed Life Sci Date: 2020-07-29 Impact factor: 3.205
Authors: E Colicino; F Ferrari; W Cowell; M M Niedzwiecki; N Foppa Pedretti; A Joshi; R O Wright; R J Wright Journal: Environ Int Date: 2021-07-10 Impact factor: 13.352
Authors: Diana C Pacyga; Joseph C Gardiner; Jodi A Flaws; Zhong Li; Antonia M Calafat; Susan A Korrick; Susan L Schantz; Rita S Strakovsky Journal: Environ Int Date: 2021-06-08 Impact factor: 13.352
Authors: Lauren C Houghton; Renata E Howland; Ying Wei; Xinran Ma; Rebecca D Kehm; Wendy K Chung; Jeanine M Genkinger; Regina M Santella; Michaela F Hartmann; Stefan A Wudy; Mary Beth Terry Journal: Cancer Epidemiol Biomarkers Prev Date: 2020-09-30 Impact factor: 4.090